Cosmo Pharmaceuticals N.V.
CMOPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $52 | $131 | $136 | $49 |
| % Growth | -60.4% | -4.2% | 177.4% | – |
| Cost of Goods Sold | $26 | -$3 | $23 | $20 |
| Gross Profit | $26 | $134 | $113 | $29 |
| % Margin | 50.6% | 102.5% | 83% | 58.3% |
| R&D Expenses | $18 | -$10 | $11 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $14 | -$9 | $16 | $28 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | -$5 | $91 | -$1 | -$10 |
| Operating Expenses | $28 | $72 | $26 | $29 |
| Operating Income | -$1 | $62 | $87 | -$1 |
| % Margin | -2.7% | 47.4% | 63.8% | -2% |
| Other Income/Exp. Net | $1 | $3 | $2 | -$1 |
| Pre-Tax Income | -$1 | $65 | $89 | -$2 |
| Tax Expense | $1 | $7 | $13 | $4 |
| Net Income | -$2 | $57 | $76 | -$6 |
| % Margin | -3.9% | 43.8% | 55.8% | -13.1% |
| EPS | -0.13 | 3.45 | 4.7 | -0.4 |
| % Growth | -103.8% | -26.6% | 1,275% | – |
| EPS Diluted | -0.13 | 3.43 | 4.71 | -0.4 |
| Weighted Avg Shares Out | 16 | 16 | 16 | 16 |
| Weighted Avg Shares Out Dil | 16 | 16 | 16 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | -$1 |
| Depreciation & Amortization | $6 | $5 | $7 | $7 |
| EBITDA | $5 | $71 | $94 | $6 |
| % Margin | 9.4% | 54.7% | 69.2% | 11.5% |